Satisfaction and perceived effectiveness in patients on subcutaneous immunotherapy with a high-dose hypoallergenic pollen extract.
This study was designed to determine the level of satisfaction, tolerance and perceived effectiveness by patients in the first pollen season after starting treatment with Alergovit(®). For this purpose, a nationwide, retrospective, multicentre and cross-sectional observational study was carried on 256 patients. Perceived effectiveness by the patients was measured using a visual analogue scale and was clinically significant in 92.4% of the patients. The satisfaction level was evaluated with a specific questionnaire. 32.5% of the patients were totally satisfied with Allergovit(®) and 48.8% reported a high degree of satisfaction. The treatment was well tolerated by 99.2% of the patients. Our results demonstrate that subcutaneous immunotherapy with Allergovit(®) is effective and well-tolerated in routine clinical practice.
Hospital Universitario Puerta de Hierro Majadahonda, Servicio de Alergia, Majadahonda, Spain. Phone: +34 91 191 68 04 Fax: +34 91 373 46 61 E-mail: mrodriguezm.hpth@salud.madrid.org.
M
M
Rodríguez Mosquera
Hospital Universitario Ramón y Cajal, Servicio de Alergia, Madrid, Spain.
F J
FJ
Sola Martínez
Hospital central de la defensa Gómez Ulla, Instituto Mixto de Investigación del Defensa IMIDEF, Servicio de Alergia, Madrid, Spain.
A
A
Montoro de Francisco
Facultad de Medicina, Universidad CEU San Pablo, Madrid, Spain.
T
T
Chivato Pérez
Hospital Universitario del Henares Madrid, Servicio de Alergología, Madrid, Spain.
V
V
Sánchez Moreno
Departamento Médico, Merck SL, Madrid, Spain.
A
A
Rodríguez-Marco
Departamento Médico, Merck SL, Madrid, Spain.
J
J
Hernández-Peña
D000293:Adolescent; D000328:Adult; D000485:Allergens / Q000008:administration & dosage* / Q000009:adverse effects; D052179:Antigens, Plant / Q000008:administration & dosage* / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D003888:Desensitization, Immunologic / Q000379:methods*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010465:Perception; D012189:Retrospective Studies; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis / Q000276:immunology / Q000523:psychology / Q000628:therapy*; D018570:Risk Assessment; D012307:Risk Factors; D013030:Spain; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014612:Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D055815:Young Adult
D000485:Allergens; D052179:Antigens, Plant; D015415:Biomarkers; D014612:Vaccines; C099681:allergovit; D007073:Immunoglobulin E
Allergoid; effectiveness; high-dose; hypoallergenic; perceived effectiveness; subcutaneous immunotherapy (SCIT)